Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study. (2020). SKIN The Journal of Cutaneous Medicine, 4(6), s82. https://doi.org/10.25251/skin.4.supp.82